Payment overview · 2025
General Payments
$492.65
23 reported records · 12 companies
Healthcare provider profile · identity verified
Lance Martin, M.D.
Allopathic & Osteopathic Physicians|Emergency Medicine · AMARILLO, TX · NPI 1104147990
Verified facts
What the public records show
CMS Open Payments records show Lance Martin, M.D. received $492.65 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.93 | 34.3% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $65.53 | 13.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.95 | 10.8% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $37.33 | 7.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.06 | 7.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.84 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.74 | 4.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.68 | 3.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.59 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.77 | 3.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.84 | 3.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.39 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $492.65 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $100.63 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.30 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $65.53 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.95 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $37.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 87 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1102 | 305 |
| Levothyroxine Sodium | Levothyroxine Sodium | 688 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 432 | 117 |
| Lisinopril | Lisinopril | 363 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 116 |
| Losartan Potassium | Losartan Potassium | 336 | 94 |
| Gabapentin | Gabapentin | 306 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 83 |
| Metformin Hcl Er | Metformin Hcl | 288 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 85 |
| Omeprazole | Omeprazole | 281 | 83 |
| Potassium Chloride | Potassium Chloride | 276 | 79 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 273 | 79 |
| Alendronate Sodium | Alendronate Sodium | 243 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 240 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 69 |
| Doxycycline Hyclate | Doxycycline Hyclate | 227 | 180 |
| Tramadol Hcl | Tramadol Hcl | 224 | 60 |
| Furosemide | Furosemide | 220 | 75 |
| Montelukast Sodium | Montelukast Sodium | 212 | 81 |
| Carvedilol | Carvedilol | 207 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 58 |
| Metformin Hcl | Metformin Hcl | 191 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 66 |
| Simvastatin | Simvastatin | 156 | 40 |
| Allopurinol | Allopurinol | 155 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 151 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 150 | 38 |
| Glimepiride | Glimepiride | 147 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 32 |
| Celecoxib | Celecoxib | 145 | 49 |
| Trazodone Hcl | Trazodone Hcl | 138 | 39 |
| Meloxicam | Meloxicam | 128 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 33 |
| Famotidine | Famotidine | 112 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 34 |
| Ezetimibe | Ezetimibe | 103 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 99 | 32 |
| Jardiance | Empagliflozin | 97 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 33 |
| Prednisone | Prednisone | 91 | 73 |
| Eliquis | Apixaban | 87 | 26 |
| Ozempic | Semaglutide | 83 | 23 |
| Pregabalin | Pregabalin | 77 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 16 |
| Spironolactone | Spironolactone | 74 | 28 |
| Donepezil Hcl | Donepezil Hcl | 71 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 69 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 40 |
| Sertraline Hcl | Sertraline Hcl | 67 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 53 |
| Estradiol | Estradiol | 57 | 23 |
| Lovastatin | Lovastatin | 56 | 17 |
| Azelastine Hcl | Azelastine Hcl | 54 | 34 |
| Ondansetron Odt | Ondansetron | 54 | 34 |
| Propranolol Hcl | Propranolol Hcl | 54 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 41 |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 28 |
| Nystatin | Nystatin | 51 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 12 |
| Eszopiclone | Eszopiclone | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | 12 |
| Azithromycin | Azithromycin | 45 | 41 |
| Mupirocin | Mupirocin | 45 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 18 |
| Methocarbamol | Methocarbamol | 36 | 15 |
| Benazepril Hcl | Benazepril Hcl | 34 | 11 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 20 |
| Testosterone | Testosterone | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Fluorouracil | Fluorouracil | 29 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | 12 |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $492.65 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, INSPIRE, KRYSTEXXA, Leqembi, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, VOQUEZNA, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error